RecruitingNCT07180264

Trastuzumab Deruxtecan in Advanced Breast Cancer

Trastuzumab Deruxtecan in Patients With Advanced Breast Cancer: a Real-world Study

Sponsor

Wenjin Yin

Enrollment

118 participants

Start Date

Aug 28, 2025

Study Type

OBSERVATIONAL

Conditions

Advanced Breast Cancer

Summary

To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is an observational study following breast cancer patients who are treated with trastuzumab deruxtecan (T-DXd), a targeted antibody-drug combination, as part of their regular cancer care. It aims to collect real-world data on how well the treatment works and its side effects outside of a controlled trial setting. **You may be eligible if...** - You are 18 or older - You have been diagnosed with breast cancer and your doctor recommends trastuzumab deruxtecan as part of your treatment - You are in reasonably good health (ECOG 0-1) **You may NOT be eligible if...** - You are currently pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTrastuzumab deruxtecan

Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.

Locations(1)

Renji Hospital, School of Medicine, Shanghai Jiaotong University

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07180264

Related Trials

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT042224132 locations

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

NCT0699702921 locations

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

NCT073188059 locations

A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer

NCT075405331 location

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751298 locations